Evidence map›Paper›PMID 40498983›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

KRAS mRNA Spleen-Targeting Lipid Nanoparticles Synergize with Irinotecan Silicasomes to Robustly Augment the Cancer Immunity Cycle in Pancreatic Cancer.

Lijia Luo, Xiang Wang, Yu-Pei Liao, Andre E Nel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lijia LuoDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0001-7125-6562
Xiang WangCalifornia NanoSystems Institute, University of California, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0002-6647-0684
Yu-Pei LiaoDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0001-7239-9426
Andre E NelDivision of Nanomedicine, Department of Medicine, University of California, Los Angeles, CA, 90095, USA.ORCID https://orcid.org/0000-0002-5232-4686

Funding

Use of a Nano-Enabled Platform for Pancreatic Cancer ImmunotherapyR01CA247666 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEL, ANDRE ELIAS, ZINK, JEFFREY I · 2020 to 2024
$2.6M
National Cancer Institute in the USANCI NIH HHS R01 CA247666U.S. Public Health Service R01CA247666-03
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies due to its immunosuppressive tumor microenvironment. It is hypothesized that overcoming these barriers requires a dual approach: inducing immunogenic tumor cell death (ICD) and enhancing the cancer immunity cycle by exogenous neoantigen targeting on the spleen. In this study, a novel strategy is presented combining irinotecan-loaded silicasomes with spleen-targeting lipid nanoparticles (LNPs) carrying KRAS

Indexed as

IrinotecanNanoparticle Drug Delivery SystemPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)Topoisomerase I InhibitorsAnimalsCarcinoma, Pancreatic DuctalCell Line, TumorEndoplasmic Reticulum StressFemaleHumansLiposomesMice, Inbred C57BLNanoparticlesRNA, MessengerSpleenIrinotecanLipid NanoparticlesLiposomesNanoparticle Drug Delivery SystemProto-Oncogene Proteins p21(ras)RNA, MessengerToll-Like Receptor 7Toll-Like Receptor 8Topoisomerase I Inhibitorscancer immunity cycledual drug silicasomeimmunotherapylipid nanoparticlesmRNA deliverypancreatic cancerTLR agonists

Identifiers

PMID40498983
PMCPMC12442683

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.